Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly: Improvements in Daily Functioning and Quality of Life

References

• Kress HG , AhlbeckK , AldingtonDet al. Managing chronic pain in elderly patients requires a CHANGE of approach. Curr. Med. Res. Opin.30, 1153–1164 (2014).
   PubMed Web of Science ®Google Scholar
• Langley P , Müller-SchwefeG , NicolaouA , LiedgensH , PergolizziJ , VarrassiG. The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization. J. Med. Econ.13, 571–581 (2010).
   PubMedGoogle Scholar
• Global Burden of Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet390, 1211–1259 (2017).
   PubMed Web of Science ®Google Scholar
• World Health Organization . Chronic rheumatic conditions. http://www.who.int/chp/topics/rheumatic/en/
   Google Scholar
• Osteoarthritis Research Society International . Osteoarthritis: a serious disease. https://www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf
   Google Scholar
• Afilalo M , EtropolskiMS , KuperwasserBet al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee. Clin. Drug Investig.30, 489–505 (2010).
   PubMed Web of Science ®Google Scholar
• Wild JE , GrondS , KuperwasserBet al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10, 416–427 (2010).
   PubMed Web of Science ®Google Scholar
• Steigerwald I , MüllerM , KujawaJ , BalblancJC , Calvo-AlénJ. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, Phase 3b study. J. Pain Res.5, 121–138 (2012).
   PubMedGoogle Scholar
• Steigerwald I , SchenkM , LahneU , GebuhrP , FalkeD , HoggartB. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin. Drug Investig.33, 607–619 (2013).
   PubMed Web of Science ®Google Scholar
• Buynak R , RappaportSA , RodKet al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Ther.37, 2420–2438 (2015).
   PubMed Web of Science ®Google Scholar
• Stollenwerk A , SohnsM , HeisigF , EllingC , von ZabernD. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv. Ther.35, 12–30 (2018).
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium . Palexia SR prolonged release tablets. Summary of product characteristics. https://www.medicines.org.uk/emc/medicine/28373
   Google Scholar
• Kneip C , TerlindenR , BeierH , ChenG. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab. Lett.2, 67–75 (2008).
   PubMedGoogle Scholar
• Smit JW , OhC , RengelshausenJet al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy30, 25–34 (2010).
   PubMed Web of Science ®Google Scholar
• De Salve A . Tapentadol PR in fragile over eighty years old patients with non-cancer chronic pain. Poster presented at: 8th World Congress of the World Institute of Pain. Hilton, NY, USA, 20–23 May 2016.
   Google Scholar
• Biondi DM , XiangJ , EtropolskiM , MoskovitzB. Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain. J. Opioid Manag.11, 393–403 (2015).
   PubMedGoogle Scholar
• Lange B , SohnsM , TemperoJ , EllingC. Treatment of moderate to severe chronic osteoarthritis knee pain with tapentadol prolonged release in elderly patients – a pooled analysis of two double-blind, randomized, placebo- and active-controlled studies. Curr. Med. Res. Opin.34, 2113–2123 (2018).
   PubMed Web of Science ®Google Scholar
• Lange T , KringsD , Waldmann-RexS. Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain—improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy (in German). MMW Fortschr. Med.157, 12–21 (2015).
   PubMedGoogle Scholar
• Grünenthal GmbH . Fachinformation Palexia® retard (German summary of product characteristics) (2010).
   Google Scholar
• Ware J Jr , KosinskiM , KellerSD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care34, 220–233 (1996).
   PubMed Web of Science ®Google Scholar
• Gandek B , WareJE , AaronsonNKet al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. J. Clin. Epidemiol.51, 1171–1178 (1998).
   PubMed Web of Science ®Google Scholar
• Kiresuk TJ , ShermanRE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment. Health J.4, 443–453 (1968).
   PubMed Web of Science ®Google Scholar
• Nagel B , PfingstenM , LindenaG , NilgesP. German pain questionaire (in German). Manual. 2012. https://pdfslide.net/documents/handbuch-dgssorg-dsf-deutscher-schmerz-fragebogen-april-2012-343-anhang-zum.html
   Google Scholar
• Baron R , EberhartL , KernKUet al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract.17, 678–700 (2017).
   PubMed Web of Science ®Google Scholar
• Lange B , von ZabernD , EllingC , DuboisC. Efficacy and safety of tapentadol prolonged released for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr. Med. Res. Opin.33, 1413–1422 (2017).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM , ChristophT , KögelBY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs28, 319–329 (2014).
   PubMed Web of Science ®Google Scholar
• Raffa RB , EllingC , TzschentkeTM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘μ-load’. Adv. Ther.35, 1471–1484 (2018).
   PubMed Web of Science ®Google Scholar
• Wise BL , ParimiN , ZhangYet al. Frailty and hip osteoarthritis in men in the MrOS cohort. J. Gerontol. A Biol. Sci. Med. Sci.69, 602–608 (2014).
   PubMed Web of Science ®Google Scholar
• Misra D , FelsonDT , SillimanRAet al. Knee osteoarthritis and frailty: findings from the multicenter osteoarthritis study and osteoarthritis initiative. J. Gerontol. A Biol. Sci. Med. Sci.70, 337–342 (2015).
   Web of Science ®Google Scholar
• European Public Health Association . Falls among older adults in the EU-28: key facts from the available statistics. https://eupha.org/repository/sections/ipsp/Factsheet_falls_in_older_adults_in_EU.pdf
   Google Scholar
• Leveille SG , JonesRN , KielyDKet al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA302, 2214–2221 (2009).
   PubMed Web of Science ®Google Scholar
• Rolita L , SpegmanA , TangX , CronsteinBN. Increasing narcotic analgesic prescriptions for osteoarthritis is associated with increased falls and fractures in the elderly. J. Am. Geriatr. Soc.61, 335–340 (2013).
   PubMed Web of Science ®Google Scholar